Gamifant Emapalumab Application Scope

Gamifant (Emapalumab) is a monoclonal antibody specifical primary hemophagocytic lymphohistiocytosis (HLH), a rare and life-thEmapalumab works by inhibiting the action of intinterferon-gamma (IFN-γ), a key inflammatory cytokine involved in the pathogenesis of HLH. It helps to suppress excessive immune activation, reduce inflammation, and prevent organ damage.

Gamifant is used to treat familial HLH and secondary HLH in patients who have an inadequate response to conventional therapies, such as immuno-suppressing immune suppressants or chemotherapy.

Gamifant Emapalumab Characteristics

Ingredients:
- Active ingredient: Emap
- Excipients: Sodium chloride, sodium citrate, and other stabilizers.
Properties: Emapalumab is a monoclonal antibody that binds to and neutralizes interferon-gamma
Specification: Available as single-use vials containing 100 mg/10 mL of solution for infusion.
Storage:
- Store the vials in a refrigerator at 2°C to 8°C.
- Do not freeze. Protect from light.
Expiry Date: Shelf life is typically 24 months; check packaging for specific expiry dates.
Executive Standard: Meets regulatory standards set by FDA and other international health authorities.
Approval Number: Specific approval number from FDA or other relevant regulatory bodies.
Manufacturer: Swedish Orphan Biovitrum (Sobi)

Guidelines For The Use Of Gamifant Emapalumab

Dosage and Administration:

- The initial dose is typically 3 mg/kg administered every week via intravenous infusion. The dose may be adjusted based on patient response.
- Infusions should be administered under the supervision of a healthcare provider who is familiar with the management of HLH.

Adverse Reactions:

- Common side effects include fever, headache, infection, injection site reactions, and gastrointestinal symptoms such as nausea and diarrhea.
- Rare but serious adverse effects include infusion reactions, immune system dysfunction, and potential organ toxicity.

Medication Limitations

Contraindications:

Hypersensitivity to Emapalumab or any components of the formulation.
Not recommended for patients with severe uncontrolled infections or those who have a history of severe allergic reactions to monoclonal antibodies.

Precautions:

Hypersensitivity to Emapalumab or any components of the formulation.
Not recommended for patients with severe uncontrolled infections or those who have a history of severe allergic reactions to monoclonal antibodies.

Gamifant Emapalumab Interactions

Drug Interactions:

No significant drug-drug interactions have been identified in clinical trials, but caution should be taken when used with other immunosuppressive drugs or treatments that affect the immune system.
Use with caution in combination with live vaccines, as immunosuppression can impair the ability to mount an immune response.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from HongKong DengYue Medicine. It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.